|
Caliway Biopharma, founded in 2012, is a biotechnology company specializing in the development of new drugs for aesthetic medicine and chronic inflammatory diseases. The company focuses on indications with unmet medical needs, including local fat reduction, weight management, cellulite treatment, and Dercum's Disease. Its lead product, CBL-514, is an injectable small-molecule drug that induces adipocyte apoptosis to reduce subcutaneous fat. CBL-514 has completed Phase 2 clinical trials for abdominal fat reduction, cellulite, and Dercum's Disease, and has received FDA Fast Track and Orphan Drug Designations for the latter. The company has initiated global Phase 3 trials for abdominal fat reduction and is exploring combinations with GLP-1 receptor agonists for weight management. Additional pipeline candidates include long-acting injectables for skin whitening, anti-aging, and degenerative joint disease. Caliway Biopharma targets markets in Asia and globally, with patent protection extending to 2045. Summarised from the company's own disclosures, fiscal year ended Oct 2026 |
Industry Biotechnology | Homepage caliwaybiopharma.com |
| Sector Healthcare | IR page caliwaybiopharma.com/investor | |
|
Tags
aesthetic medicine, adipocyte apoptosis, local fat reduction, weight management, cellulite treatment, dercum's disease, small-molecule drugs, injectable formulations, chronic inflammatory diseases, skin whitening, anti-aging, degenerative joint disease, CBL-514, SUPREME-01, SUPREME-02, CBL-0205, CBL-0204, CBL-0301, CBL-0202DD, CBL-0206
|
Press page — |
Metrics
| Valuation | |
|---|---|
| Market cap | NT$ 111.585B |
| Market cap (USD) | $ 3.387B |
| P/E | -179.00 |
| PEG | — |
| P/BV | 12.72 |
| P/S | — |
| P/OCF | -213.64 |
| P/FCF | — |
| Dividend yield | — |
| Turnover / mcap | — |
| Returns | |
|---|---|
| ROE | -3.7% |
| ROI | -3.7% |
| ROIC | -5.6% |
| Profit margin | -925.2% |
| Growth | |
|---|---|
| Revenue growing | No |
| Profits growing | Yes |
| Revenue up 3y | No |
| Revenue up 5y | — |
| Earnings growth 3y (net profit CAGR) | — |
| Quality | |
|---|---|
| Profitable | No |
| Margin expanding | No |
| Buying back stock | No |
| Diluting (TTM) | No |
| Debt/Equity | — |
| Podcast bulls (TTM) | Sign up |
| Podcast bears (TTM) | Sign up |
| Podcast sentiment (TTM) | Sign up |
| Podcast sentiment % (TTM) | Sign up |
| News sentiment (TTM) | 0 |
| Quality score | -60.0% |
| Insiders | |
|---|---|
| Buys, 1w | Sign up |
| Buys, 1m | Sign up |
| Buys, 1y | Sign up |
| Sells, 1w | Sign up |
| Sells, 1m | Sign up |
| Sells, 1y | Sign up |
Sign up to see this company's insider trades
| Figure | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | 38.037M | 44.434M | 38.932M | 12.82M | 12.339M |
| Net profit | -351.918M | -588.83M | -488.455M | -286.155M | -224.294M |
| Figure | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Share price | 155 | 615 | — | — | — |
| Price performance 12m | -0.75 | — | — | — | — |
Sign up to see institutional holdings
Sign UpPodcast Mentions
Sign up to see podcast mentions and sentiment
Sign UpMaterial information published on MOPS, newest first, subjects as filed in Chinese, guarantee and loan balance notices and routine equipment purchases included. The link opens the company's material information on MOPS. Press releases from the company's own website, newest first.
本公司近日發現,部分網路平台及第三方網站出現宣稱販售、供應或提供與本公司研發中新藥 CBL-514 相關產品之資訊,相關內容可能造成投資人、醫療專業人士及社會大眾誤解。本公司特此鄭重澄清:
CBL-514 目前仍處於臨床開發階段,尚未取得任何國家或地區之上市核准,亦尚未於任何市場上市或販售。本公司未授權任何第三方供應、販售或推廣 CBL-514,亦未授權任何第三方以本公司名義或暗示與本公司具有任何合作、授權、代理或其他關係之方式進行相關活動,任何宣稱提供或販售該產品之資訊均與本公司無關。
對於部分網站或社群媒體未經本公司授權,使用或引用本公司名稱、資料、CBL-514 相關資訊或其他資料進行產品宣傳或銷售之行為,本公司將持續關注,並將持續蒐集相關資訊及保全證據,保留依法採取相關措施之權利,以維護公司權益及避免社會大眾受到誤導。
康霈生技提醒投資人及社會大眾,應以本公司官方網站及正式公告所發布之資訊為準。對於任何非經本公司正式公告或官方管道發布之資訊,應審慎查證,切勿輕信、購買或使用來源不明之產品,以保障自身權益及安全。
特此聲明。
FOLLOW US
傳真 (02)2697-2508 ; (02)2697-1369
[email protected] [email protected]
CALIWAY. All Rights Reserved.
關鍵字搜尋
Prompts
Click prompts to add them under the company line, click again to take one out, then copy the result into your AI chat. Shared by Asian Century Stocks and Uncovered Thai Stocks. Thank you.
ETFs Holding Caliway
Exchange-traded funds whose newest published daily portfolio holds one of the company's listings, largest weight first.
| ETF | Weight in ETF | Shares | Market value | As of |
|---|---|---|---|---|
| AVXC | 0.00% | 10,000 | $ 20.428K | Nov 16, 2026 |